Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018; 378:1277e90.
doi: 10.1056/NEJMoa1712126
[2]
Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019; 380:1103e15.
doi: 10.1056/NEJMoa1816047
[3]
Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019; 380: 1116e27.
doi: 10.1056/NEJMoa1816714
[4]
Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, et al. Nivolumab plus cabozantinib versus suniti-nib for advanced renal-cell carcinoma. N Engl J Med 2021; 384: 829e41.
doi: 10.1056/NEJMoa2026982
[5]
Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 2021; 384: 1289e300.
doi: 10.1056/NEJMoa2035716
[6]
Gul A, Stewart TF, Mantia CM, Shah NJ, Gatof ES, Long Y, et al. Salvage ipilimumab and nivolumab in patients with metastatic renal cell carcinoma after prior immune checkpoint inhibitors. J Clin Oncol 2020; 38:3088e94.
doi: 10.1200/JCO.19.03315
pmid: 32491962
[7]
Ravi P, Mantia C, Su C, Sorenson K, Elhag D, Rathi N, et al. Evalu-ation of the safety and ef?cacy of immunotherapy rechallenge in patients with renal cell carcinoma. JAMA Oncol 2020; 6:1606e10.
doi: 10.1001/jamaoncol.2020.2169
[8]
Ro? E, Del Re M, Arrigoni E, Rizzo M, Fontanelli L, Crucitta S, et al. Clinical pharmacology of monoclonal antibodies targeting PD-1 axis in urothelial cancers. Crit Rev Oncol Hematol 2020; 154: 102891. https://doi.org/10.1016/j.critrevonc.2020.102891.
doi: 10.1016/j.critrevonc.2020.102891
[9]
Yearley JH, Gibson C, Yu N, Moon C, Murphy E, Juco J, et al. PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer. Clin Cancer Res 2017; 23:3158e67.
doi: 10.1158/1078-0432.CCR-16-1761
pmid: 28619999
[10]
Umezu D, Okada N, Sakoda Y, Adachi K, Ojima T, Yamaue H, et al. Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment. Cancer Immunol Immunother 2019; 68:201e11.
doi: 10.1007/s00262-018-2263-4
pmid: 30357491
